NeuroDerm: FDA Withdraws Clinical Hold On ND0612H And ND0612L - Quick Facts

(RTTNews) - NeuroDerm Ltd. (NDRM) announced the U.S. FDA has lifted the clinical hold on U.S. clinical studies of ND0612H and ND0612L, the company's primary product candidates, that are based on subcutaneously-delivered Levodopa/Carbidopa liquid formulation, for the treatment of Parkinson's disease.

The company said the hold was lifted after the FDA reviewed additional information related to the product candidates' delivery devices.

"Having lifted the clinical hold in the first half of 2015 means that our U.S. clinical development program of ND0612H and ND0612L is proceeding on track," said Oded Lieberman, CEO of NeuroDerm.